A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
Clinical trial NCT03391050 · TERMINATED
Trial details
- NCT number
- NCT03391050
- Sponsor
- Aprea Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-18
- Primary completion
- 2018-08-08
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.